risankizumab
boehringer ingelheim,abbvie
['skyrizi', 'derm', 'psoriasis', 'abbvie']
#aad2023 - #abbvie has released the results of a study that assessed the 52-week efficacy of #skyrizi in patients with plaque #psoriasis who had less response to il-17 inhibitor #therapy #pharma #pharmaceutical #healthcare #dermatology #aad23 #news #media
#iPharmaCenter is a #website which covers #pharmaceutical and #healthcare #news plus #blogs #diseases #drugs #healthcaresystems #globalhealth #pharma